Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary

McLaughlin, M.; Kelsey, T. W.; Wallace, W. H. B.; Anderson, R. A.; Telfer, E. E.
January 2017
Human Reproduction;Jan2017, Vol. 32 Issue 1, p165
Academic Journal
journal article
Study Question: Do the chemotherapeutic regimens of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) or OEPA-COPDAC (combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) used to treat Hodgkin lymphoma (HL), affect the density, morphology and in vitro developmental potential of human ovarian follicles?Summary Answer: Ovarian tissue from women treated with ABVD contained a higher density of non-growing follicles (NGFs) per cubic millimetre and increased numbers of multiovular follicles but showed reduced in vitro growth compared with patients with lymphoma who had not received chemotherapy, patients treated with OEPA-COPDAC, age-matched healthy women and age-related model-predicted values.What Is Known Already: Chemotherapy regimens can cause a loss of follicles within the ovary, which depends on the drugs given. Early stage HL is commonly treated by ABVD, a non-alkylating regimen that apparently has ovarian sparing qualities; thus it is important to investigate the histological appearance and distribution of follicles within ABVD-treated ovarian tissue.Study Design, Size, Duration: Thirteen ovarian biopsies were obtained from HL patients (six adolescents and seven adults) and one biopsy from a non-HL patient. Two HL patients and the non-HL patient had received no treatment prior to biopsy collection. The remaining 11 HL patients received one of two regimens: ABVD or OEPA-COPDAC. Tissue was analysed histologically and compared to biopsies from healthy women, and in a subgroup of patients, tissue was cultured for 6 days in vitro.Participants/materials, Setting, Methods: Ovarian biopsies were obtained from patients undergoing ovarian cryopreservation for fertility preservation and from healthy women at the time of Caesarian section ('obstetric tissue'). Follicle number and maturity were evaluated in sections of ovarian cortical tissue, and compared to an age-related model of mean follicle density and to age-matched contemporaneous biopsies. The developmental potential of follicles was investigated after 6 days of tissue culture.Main Results and the Role Of Chance: A total of 6877 follicles were analysed. ABVD-treated tissue contained a higher density of NGFs per cubic millimetre (230 ± 17) (mean ± SEM) than untreated (110 ± 54), OEPA-COPDAC-treated (50 ± 27) and obstetric (20 ± 4) tissue (P < 0.01), with follicle density 9-21 SD higher than predicted by an age-related model. Biovular and binucleated NGFs occurred frequently in ABVD-treated and in adolescent-untreated tissue but were not observed in OEPA-COPDAC-treated or obstetric tissue, although OEPA-COPDAC-treated tissue contained a high proportion of morphologically abnormal oocytes (52% versus 23% in untreated, 22% in ABVD-treated and 25% in obstetric tissue; P < 0.001). Activation of follicle growth in vitro occurred in all groups, but in ABVD-treated samples there was very limited development to the secondary stage, whereas in untreated samples from lymphoma patients growth was similar to that observed in obstetric tissue (untreated; P < 0.01 versus ABVD-treated, NS versus obstetric).Large Scale Data: N/A LIMITATIONS, REASONS FOR CAUTION: Although a large number of follicles were analysed, these data were derived from a small number of biopsies. The mechanisms underpinning these observations have yet to be determined and it is unclear how they relate to future fertility.Wider Implications Of the Findings: This study confirms that the number of NGFs is not depleted following ABVD treatment, consistent with clinical data that female fertility is preserved. Our findings demonstrate that immature follicle density can increase as well as decrease following at least one chemotherapy treatment. This is the first report of morphological and follicle developmental similarities between ABVD-treated tissue and the immature human ovary. Further experiments will investigate the basis for the marked increase in follicle density in ABVD-treated tissue.Study Funding/competing Interests: Funded by UK Medical Research Council Grants G0901839 and MR/L00299X/1. The authors have no competing interests.


Related Articles

  • Factors affecting intrapatient liver and mediastinal blood pool F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Chiaravalloti, Agostino; Danieli, Roberta; Abbatiello, Paolo; Pietro, Barbara; Travascio, Laura; Cantonetti, Maria; Guazzaroni, Manlio; Orlacchio, Antonio; Simonetti, Giovanni; Schillaci, Orazio // European Journal of Nuclear Medicine & Molecular Imaging;Jun2014, Vol. 41 Issue 6, p1123 

    Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-(F)-fluoro- D-glucose (F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD)...

  • ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 3, p82 

    The article discusses research on the safety and efficacy of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in older patients with classical Hodgkin lymphoma (cHL) who were treated within HD10 and HD11 trials. It references a study by B. Böll et al, published in a 2013 issue of...

  • Drug Combination May Help Hormone-Resistant Breast Cancer. McBride, Deborah // ONS Connect;Dec2011, Vol. 26 Issue 12, p9 

    The article reports that combining two chemotherapy drugs such as everolimus and exemestane could provide effective treatment to hormone-resistant breast cancer for post-menopausal women.

  • Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Diefenbach, Catherine S.; Connors, Joseph M.; Friedberg, Jonathan W.; Leonard, John P.; Kahl, Brad S.; Little, Richard F.; Baizer, Lawrence; Evens, Andrew M.; Hoppe, Richard T.; Kelly, Kara M.; Persky, Daniel O.; Younes, Anas; Kostakaglu, Lale; Bartlett, Nancy L. // JNCI: Journal of the National Cancer Institute;Apr2017, Vol. 109 Issue 4, p1 

    The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and...

  • Chemotherapy to the Liver Delays Progression of Metastatic Melanoma. McBride, Deborah // ONS Connect;Dec2011, Vol. 26 Issue 12, p8 

    The article reports on a study which suggests a new chemotherapy option that may delay progression of ocular melanoma liver metastases.

  • Some stage III colon cancer patients may need only half of the standard chemotherapy course. Printz, Carrie // Cancer (0008543X);Oct2017, Vol. 123 Issue 20, p3871 

    The article focuses on a study which reveals the use of half of the standard chemotherapy course for the stage III colon cancer patients and mentions that colon cancer patients may need three months of chemotherapy.

  • High-dose cisplatin in hypertonic saline. Ozols, Robert E.; Corden, Brian J.; Jacob, Joan; Wesley, Margaret N.; Ostchega, Yechian; Young, Robert C.; Ozols, R F; Corden, B J; Jacob, J; Wesley, M N; Ostchega, Y; Young, R C // Annals of Internal Medicine;Jan84, Vol. 100 Issue 1, p19 

    To overcome the dose limiting toxicity of cisplatin we have administered high-dose cisplatin (200 mg/m2 body surface area in five divided daily doses with each dose administered in 250 mL of 3% saline) together with extensive hydration (250 mL/h normal saline with 20 meq KCI/L). In 17 previously...

  • Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. Moradi Marjaneh, Reyhaneh; Hassanian, Seyed Mahdi; Ghobadi, Niloofar; Ferns, Gordon A.; Karimi, Afshin; Jazayeri, Mir Hadi; Nasiri, Mohammadreza; Avan, Amir; Khazaei, Majid // Journal of Cellular Physiology;Oct2018, Vol. 233 Issue 10, p6538 

    Despite advances in the diagnosis and treatment of colorectal cancer (CRC), it remains a major cause of cancer related death globally. There are currently no chemotherapeutic agents that have been found to eradicate the disease without adverse effects. A defect in the death receptor signaling...

  • Pegfilgrastim Prophylaxis for Cladribine-Induced Neutropenia in Patients with Hairy-Cell Leukemia. Goldschmidt, Neta; Ganzel, Chezi; attias, Dina; Gatt, Moshe; Polliack, aaron; Tadmor, Tamar // Acta Haematologica;Jun2014, Vol. 132 Issue 1, p118 

    No abstract available


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics